143 related articles for article (PubMed ID: 37427045)
21. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with avacopan (CCX168) in a pediatric patient with C3 glomerulonephritis.
Zotta F; Diomedi-Camassei F; Gargiulo A; Cappoli A; Emma F; Vivarelli M
Pediatr Nephrol; 2023 Dec; 38(12):4197-4201. PubMed ID: 37306717
[TBL] [Abstract][Full Text] [Related]
23. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.
Gonzalez Suarez ML; Thongprayoon C; Hansrivijit P; Kovvuru K; Kanduri SR; Aeddula NR; Pivovarova AI; Chewcharat A; Bathini T; Mao MA; Basu A; Cheungpasitporn W
Med Sci (Basel); 2020 Oct; 8(4):. PubMed ID: 33096866
[TBL] [Abstract][Full Text] [Related]
24. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
[TBL] [Abstract][Full Text] [Related]
25. Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy.
Kumar A; Ramachandran R; Rawat A; Das R; Rayat CS; Kenwar DB; Sharma A; Gupta KL; Nada R
Clin Kidney J; 2021 Jan; 14(1):291-300. PubMed ID: 33564431
[TBL] [Abstract][Full Text] [Related]
26. A case of C3 glomerulopathy with nephritis-associated plasmin receptor positivity without a history of streptococcal infection.
Asano M; Oda T; Mizuno M
CEN Case Rep; 2022 May; 11(2):259-264. PubMed ID: 34799818
[TBL] [Abstract][Full Text] [Related]
27. Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis.
Riedl Khursigara M; Chung E; Tjon J; Noone D; Chami R; Licht C; Teoh CW
Pediatr Nephrol; 2023 Oct; 38(10):3483-3487. PubMed ID: 36884075
[TBL] [Abstract][Full Text] [Related]
28. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
29. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
30. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
31. Predictors of poor kidney outcome in children with C3 glomerulopathy.
Pınarbaşı AS; Dursun I; Gokce I; Çomak E; Saygılı S; Bayram MT; Donmez O; Melek E; Tekcan D; Çiçek N; Yılmaz D; Tabel Y; Yıldırım ZY; Bahat E; Koyun M; Soylu A; Canpolat N; Aksu B; Çelakıl ME; Taşdemir M; Benzer M; Özçelik G; Bakkaloğlu SA; Düşünsel R
Pediatr Nephrol; 2021 May; 36(5):1195-1205. PubMed ID: 33130981
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pathological features of 52 patients with glomerulonephritis with dominant C3.
Wei J; Huang Y; Yuan S; Chen X; Fu X; Li Z; Li Y; Sun L; Liu H; Zhu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Jan; 49(1):75-83. PubMed ID: 38615169
[TBL] [Abstract][Full Text] [Related]
33. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
[TBL] [Abstract][Full Text] [Related]
34. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
[TBL] [Abstract][Full Text] [Related]
35. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
36. Durable remission of C3 glomerulonephritis with mycophenolate mofetil.
Lioufas N; Finlay M; Barbour T
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():36-39. PubMed ID: 28176473
[TBL] [Abstract][Full Text] [Related]
37. Update on C3 Glomerulopathy: A Complement-Mediated Disease.
Caravaca-Fontán F; Lucientes L; Cavero T; Praga M
Nephron; 2020; 144(6):272-280. PubMed ID: 32369815
[TBL] [Abstract][Full Text] [Related]
38. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
[TBL] [Abstract][Full Text] [Related]
39. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
Kim JS; Foster KW; Westphal SG
Clin Nephrol; 2020 Jan; 93(1):51-56. PubMed ID: 31661064
[TBL] [Abstract][Full Text] [Related]
40. Complement dysregulation in glomerulonephritis.
Kaartinen K; Safa A; Kotha S; Ratti G; Meri S
Semin Immunol; 2019 Oct; 45():101331. PubMed ID: 31711769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
